Dr. Shen’s research interest lies in developing statistical and computational genomics approaches and applications to translational cancer research. She has developed data integration methods for defining molecular subtypes of cancer and associated biomarkers across multiple “omic” data types simultaneously characterizing genomic, epigenomic, transcriptomic, and proteomic aberrations in a tumor. Her method has been used for integrative subtype analysis of breast, prostate, lung, stomach, endometrial, skin, and liver cancers in large-scale cancer genome consortium studies including the NCI/NHGRI Cancer Genome Atlas (TCGA) and the Canada-UK Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). Her recent work focuses on tumor clonal heterogeneity analysis. Together with Dr. Venkatraman Seshan, she has developed methods to unravel allele-specific copy number aberrations and clonal heterogeneity within a tumor from DNA sequencing of tumor-normal pairs that can be applied to whole-genome, whole-exome and capture sequencing platforms. Its application has shed light on the clonal status of somatic mutations and copy number alterations in lung and breast cancers as a biomarker for disease progression. Her recent research interest also includes basket trial design for biomarker-driven clinical trials in collaboration with Mithat Gönen, Colin Begg, and Alexia Iasonos.